Core Insights - Prostate cancer is the second most common malignant tumor in men globally, characterized by treatment resistance and high recurrence risk, presenting significant challenges for therapy [2] - Immune therapy has shown significant clinical benefits in various solid tumors, but its efficacy in "cold" tumors like prostate cancer remains limited, necessitating strategies to activate immune responses [2] - A recent study published in PNAS reveals that PSAT1 drives a feedback loop that enables prostate cancer cells to evade NK cell immune surveillance, providing new molecular targets and intervention strategies for treating "cold" tumors [2][10] Group 1: Research Findings - The research team found that PSAT1 is significantly overexpressed in prostate cancer tissues and correlates with poor patient prognosis, while its expression is negatively associated with the infiltration of key immune effector cells, particularly NK cells [4] - PSAT1 regulates immune evasion by enhancing the phosphorylation of YBX1, which subsequently increases PSAT1 transcription, forming a stable positive feedback loop [4] - YBX1, upon entering the nucleus, activates the expression of HLA-E, an inhibitory ligand for NK cells, leading to NK cell dysfunction and preventing their ability to kill prostate cancer cells [5] Group 2: Clinical Implications - In vitro and in vivo experiments demonstrated that targeting or inhibiting PSAT1 significantly reduces the immune evasion capability of prostate cancer cells, enhancing NK cell-mediated tumor cell killing and effectively suppressing tumor growth [6] - The combination of PSAT1 knockdown and NK cell infusion shows synergistic effects in inhibiting tumor growth, highlighting the therapeutic potential of disrupting this immune evasion pathway [6] Group 3: Future Directions - The study suggests that targeting the PSAT1-YBX1-HLA-E pathway could convert "cold" tumors into "hot" tumors that are more responsive to NK cell immunotherapy, opening new avenues for treatment [10] - Preliminary data indicate that this mechanism may also be present in other malignancies with high HLA-E expression, such as lung cancer and glioma, suggesting broader therapeutic potential [10]

Core Insights - The study published in the journal "Cell" reveals that melanoma cells secrete large extracellular vesicles (melanosomes) that express major histocompatibility complex (MHC) molecules, which stimulate CD8+ T cells through T cell receptors (TCR), leading to T cell dysfunction and apoptosis [3] Group 1: Immune Evasion Mechanism - Melanoma cells utilize MHC export to protect themselves from cytotoxic T cell attacks, revealing a novel immune evasion mechanism [3][7] - The research indicates that melanosomes carry tumor-associated antigens with higher affinity and immunogenicity, competing directly with TCR-MHC interactions [3] Group 2: Impact of Inhibiting Melanosome Secretion - Inhibition of melanosome secretion significantly reduces tumor immune evasion, enhancing the effectiveness of CD8+ T cells in the tumor microenvironment [3][7] - The use of the depigmenting agent kojic acid, which blocks melanin production, resulted in decreased melanosome secretion without affecting melanoma proliferation or MHC I expression [4][5] Group 3: Experimental Findings - In mouse models, the inhibition of melanosome secretion led to increased infiltration of CD8+ T cells into the tumor microenvironment and slowed tumor growth [5][7] - The study demonstrates that blocking melanosome secretion can enhance the activity and effectiveness of tumor-infiltrating CD8+ T cells [7]

Core Viewpoint - The recent research reveals that Mycobacterium tuberculosis actively secretes linoleic acid to manipulate host immune responses, enhancing regulatory T cell (Treg) function and promoting bacterial survival within macrophages, thus providing new targets for tuberculosis treatment [3][6][10]. Group 1: Research Findings - The study published in Nature Microbiology identifies a novel mechanism by which Mycobacterium tuberculosis uses linoleic acid to upregulate CTLA-4 expression in Treg cells, thereby suppressing the host's anti-tuberculosis immune response [3][6]. - The research demonstrates that the bacterium is not merely evading the immune system but is actively creating a favorable intracellular environment for its survival by secreting specific metabolites [6][10]. - Increased levels of cytoplasmic calcium ions in Treg cells, triggered by linoleic acid, lead to enhanced CTLA-4 expression, which further inhibits immune responses, allowing the bacteria to persist within macrophages [7][8]. Group 2: Implications for Treatment - The findings suggest that targeting the mechanisms involving Rv1272c, linoleic acid, ATP2a3, and CTLA-4 could lead to the development of new therapeutic strategies against tuberculosis [10]. - This research opens up new avenues for designing drugs that can disrupt the immune suppression caused by Mycobacterium tuberculosis, potentially improving treatment outcomes for tuberculosis patients [10].